Continuous glucose monitoring (CGM) with (black) and without (gray) pasireotide therapy. The plot shows the in-hospital glucose sensor-level time courses recorded while the patient was assuming DZX 225 mg/d (period A; 4 days; gray line) or DZX 75 mg/d + pasireotide 0.6 mg twice per day (BID; period C; 4 days; black line). Period B is not shown for visual clarity, and it is detailed in Table 1. Note that period C was characterized by an episode of severe hypoglycemia and by recurrent “saw blade” glycemic phases, reflecting mild–moderate hypoglycemic episodes, promptly corrected by the patient with repeated oral glucose intake.